Akebia Therapeutics (AKBA) Misses Q4 EPS by 32c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. CVI
10. HNGE

Go back to Akebia Therapeutics (AKBA) Misses Q4 EPS by 32c

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

March 10, 2020 7:49 AM EDT

Top-line data readouts of global Phase 3 program for vadadustat on track for Q2 of 2020 and mid-2020 Company extends cash runway well into 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney... More